Autolus Therapeutics
Price & Volume
Stats
See moreOpen | $2.46 |
Previous Close | $2.42 |
Day Range | $2.39-$2.48 |
52W Range | $1.10-$5 |
Market Cap | $649.3M |
Shares Short | 13M |
Financials
See moreRevenue (12 Mos) | $9M |
Revenue Growth (YoY) | -11% |
Gross Profit (12 Mos) | -$146M |
Diluted EPS | -$0.88 |
News
See moreYahoo Finance • 3 days ago
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance • 2 months ago
SA Asks: Which oncology companies are attractive M&A targets?
Yahoo Finance • 2 months ago
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Yahoo Finance • 3 months ago
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
About
CEO | Dr. Christian Martin Itin Ph.D. |
CFO | Mr. Robert F. Dolski |
Address | The Mediaworks, London, United Kingdom, W12 7FP |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 647 |
